Illumina is studying how genetics sequencing technology can help track infected populations; therapeutics maker Alexion is conducting Phase 3 trials for its Ultomiris drug to treat pneumonia in Covid-19 patients.“These companies have good prospects and a high probability of outperforming the market over the next nine months.” Even so, the ETF’s heavy tilt towards just a handful of companies—aside from the concentration in those four stocks, 50% of assets are in the top 10 holdings—can create volatility and present other risks.